Biotech developer Curis (CRIS +5%) gets a lift after saying it's entered into an agreement with...
Biotech developer Curis (CRIS +5%) gets a lift after saying it's entered into an agreement with The Leukemia & Lymphoma Society to support the ongoing development of its oral small molecule dual Pi3K and HDAC inhibitor CUDC-907, a treatment for patients with B-cell lymphoma and multiple myeloma.
From other sites
at CNBC.com (Mar 31, 2014)
at CNBC.com (Nov 6, 2013)
at CNBC.com (Jul 29, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs